Document is current
Any future updates will be listed below
-
Authors
Nero, Camilla
Vizzielli, Giuseppe
Lorusso, Domenica
Cesari, Eleonora
Daniele, Gennaro
Loverro, Matteo
Scambia, Giovanni
Sette, Claudio https://orcid.org/0000-0003-2864-8266
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG23416)
Ministero della Salute (GR-2019-12371435)
Università Cattolica del Sacro Cuore (Linea D1, Linea 3.1)
- License Information
-
More Information
Article History
Received: 3 February 2021
Accepted: 17 March 2021
First Online: 31 March 2021
Declarations
:
: Not applicable.
: Not applicable.
: - C. Nero, G. Vizzielli, C. Sette, E. Cesari, M. Loverro have no conflict of interest to declare.- G. Daniele has served on advisory board of Beigene and received support for travel and accomodation from Roche.- G Scambia has served on advisory boards for TESARO Bio Italy S.r.l,Johnson & Johnson, Clovis Oncology Italy S.r.l. He received support.for travel or accommodation from MSD Italy S.r.l and Clovis.Oncology Italy S.r.l, and institutional research funding from MSD Italy S.r.l.- D. Lorusso has served on advisory boards for Clovis Oncology,AstraZeneca, Genmab/Seattle Genetics, MSD, ImmunoGen,PharmaMar, Roche, and Tesaro/GSK, received support for travel or.accommodation from AstraZeneca, GSK and Roche and institutional.research funding from Merck, GSK, Clovis, Pharmamar.
